| Date Filed | Type | Description |
| 01/11/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 12/21/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 12/12/2022 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 11/21/2022 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 11/22/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/17/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/08/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/29/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/12/2021 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 10/01/2021 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 09/30/2021 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 04/01/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 03/22/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 03/04/2021 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 03/04/2021 |
3
| Merck & Co., Inc. (10% Owner) has filed a Form 3 on Pandion Therapeutics, Inc. |
| 02/25/2021 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 05/02/2012 |
ARS
| Form ARS - Annual Report to Security Holders |
| 04/05/2011 |
BW
| Merck to Acquire Inspire Pharmaceuticals, Inc. |
| 04/01/2011 |
BW
| Merck to Hold First-Quarter 2011 Sales and Earnings Conference Call on April 29 |
| 03/31/2011 |
BW
| New Data Analyses with VICTRELIS™ (boceprevir), Merck's Investigational Medicine, Examined Possible Predictors of Sustained Virologic Response |
| 03/31/2011 |
BW
| VICTRELIS™ (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control |
| 03/24/2011 |
BW
| ADDING and REPLACING FDA Expands Indication for ZOSTAVAX®, Merck's Shingles Vaccine, to Include Adults Ages 50 to 59 |
| 03/24/2011 |
BW
| Portola Pharmaceuticals to Regain Global Rights for Investigational Medicine Betrixaban from Merck |
| 03/22/2011 |
BW
| Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health |
| 03/18/2011 |
BW
| Committee for Medicinal Products for Human Use (CHMP) Issues Positive Opinion for New Contraception Offering, NOMAC-E2 |
| 03/17/2011 |
PRN
| Critical Alerts for Merck, First Solar, Whole Foods, Riverbed Technology, and Maxim Integrated Products Released By Seven Summits Research |
| 03/15/2011 |
BW
| Merck to Present at Barclays Capital 2011 Global Healthcare Conference |
| 03/07/2011 |
BW
| Merck Announces New Data Analyses for VICTRELIS™ (Boceprevir) will be Presented at The International Liver CongressTM / 2011 EASL Annual Meeting |
| 03/01/2011 |
BW
| Merck's ISENTRESS® (raltegravir) Demonstrated Durable Reductions in HIV-1 Viral Load and Sustained Tolerability At Three Years of Treatment in Previously Untreated Adult Patients Infected with HIV-1 |
| 02/28/2011 |
BW
| Merck to Present at Citi 2011 Global Health Care Conference |
| 02/28/2011 |
BW
| Fujifilm to Acquire Merck Biomanufacturing Network |
| 02/25/2011 |
NO ACT
| Form NO ACT - No Action Letter |
| 02/22/2011 |
BW
| Merck Announces Second Quarter 2011 Dividend |
| 02/14/2011 |
BW
| Merck Wins First FOSAMAX® (alendronate sodium) State Court Trial |
|